Excessive sweating is a symptom of hyperhidrosis, a disorder in which a person sweats excessively. The face, hands, feet, and armpits are the most commonly affected areas. Sweating can be localized (happens only in a certain location) or generalized (happens everywhere). Primary axillary hyperhidrosis and subsequent global hyperhidrosis are the two kinds. Wet feet, palms, and soles, as well as excessive perspiration, are some of the signs of hyperhidrosis. Hyperhidrosis can be present from birth or develop later in life. Its serious repercussions could result in bacterial or fungal infections. Heart disease, mental disorders, obesity, and infectious diseases such as malaria and tuberculosis are among the causes of hyperhidrosis.
Market Drivers for Hyperhidrosis Treatment Around the World
The worldwide Hyperhidrosis Treatment Market is likely to rise as key companies focus on creating innovative solutions for the treatment of hyperhidrosis. Dermira Inc., for example, developed Qbrexa cloth in October 2018 for the treatment of primary axillary hyperhidrosis. It contains the anticholinergic medication glycopyrronium and is suitable for both adults and children (aged 9 years and above). It was approved by the US Food and Drug Administration in June of 2018.
In addition, GlaxoSmithKline concluded its phase II clinical trials investigation of Umeclidinium for the treatment of hyperhidrosis in December 2016. The study's goal was to assess the drug's effectiveness, pharmacokinetics, and tolerability in individuals with primary axillary hyperhidrosis. A minimum of 50% perspiration reduction was found in roughly seven patients on the 15th day of treatment, according to the study. As a result, such advancements are projected to propel the worldwide hyperhidrosis treatment market's growth in the coming years.
Regional Analysis of the Global Hyperhidrosis Treatment Market
Because of the existence of significant players such as Brickell Biotech Inc., Dermira Inc., and others, North America is projected to hold a dominating position in the global hyperhidrosis market. These significant players are concentrating on adjusting expansion tactics such as mergers, acquisitions, partnerships, and collaborations, among other things. Brickell Biotech, Inc., a clinical-stage pharmaceutical firm, combined with Vical Inc., a biopharmaceutical company, in June 2019. The merger's goal was to create new treatments for hyperhidrosis and other dermatological problems.
The worldwide Hyperhidrosis Treatment Market is likely to rise as key companies focus on creating innovative solutions for the treatment of hyperhidrosis. Dermira Inc., for example, developed Qbrexa cloth in October 2018 for the treatment of primary axillary hyperhidrosis. It contains the anticholinergic medication glycopyrronium and is suitable for both adults and children (aged 9 years and above). It was approved by the US Food and Drug Administration in June of 2018.
In addition, GlaxoSmithKline concluded its phase II clinical trials investigation of Umeclidinium for the treatment of hyperhidrosis in December 2016. The study's goal was to assess the drug's effectiveness, pharmacokinetics, and tolerability in individuals with primary axillary hyperhidrosis. A minimum of 50% perspiration reduction was found in roughly seven patients on the 15th day of treatment, according to the study. As a result, such advancements are projected to propel the worldwide hyperhidrosis treatment market's growth in the coming years.
Regional Analysis of the Global Hyperhidrosis Treatment Market
Because of the existence of significant players such as Brickell Biotech Inc., Dermira Inc., and others, North America is projected to hold a dominating position in the global hyperhidrosis market. These significant players are concentrating on adjusting expansion tactics such as mergers, acquisitions, partnerships, and collaborations, among other things. Brickell Biotech, Inc., a clinical-stage pharmaceutical firm, combined with Vical Inc., a biopharmaceutical company, in June 2019. The merger's goal was to create new treatments for hyperhidrosis and other dermatological problems.
Key Players in the Global Hyperhidrosis Treatment Market
Allergan plc, Theravida Inc., GlaxoSmithKline plc, Kaken Pharmaceutical Co., Ltd., Brickell Biotech, Inc., Dermira, Inc., Revance Therapeutics, Inc., Avanor Healthcare Ltd., Ulthera, Inc., and Dr. August Wolff GmbH are some of the main competitors in the global hyperhidrosis treatment market.
Allergan plc, Theravida Inc., GlaxoSmithKline plc, Kaken Pharmaceutical Co., Ltd., Brickell Biotech, Inc., Dermira, Inc., Revance Therapeutics, Inc., Avanor Healthcare Ltd., Ulthera, Inc., and Dr. August Wolff GmbH are some of the main competitors in the global hyperhidrosis treatment market.
0 Comments